Development of gene therapy to target pancreatic cancer

Cancer Science

Volumn 95, Issue 4, 2004, Pages 283-289

  Yoshida, Teruhiko ^a   Ohnami, Shumpei ^a   Aoki, Kazunori ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; BETA INTERFERON; COMPLEMENTARY RNA; CYTOKINE; GANCICLOVIR; K RAS PROTEIN; LIPOSOME; RECOMBINANT INTERFERON; THYMIDINE KINASE;

CANCER CELL CULTURE; CANCER GENETICS; CANCER INFILTRATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG SAFETY; EXPRESSION VECTOR; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; IN VIVO STUDY; METASTASIS; MOLECULAR DYNAMICS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOGENE K RAS; PANCREAS CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TISSUE SPECIFICITY; TRANSGENE; TUMOR IMMUNITY; VIRAL GENE DELIVERY SYSTEM;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; CARRIER PROTEINS; CYTOKINES; DRUG CARRIERS; GENE LIBRARY; GENE THERAPY; GENES, RAS; GENETIC VECTORS; HUMANS; INTERFERONS; LIPIDS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; PERITONEAL NEOPLASMS; POINT MUTATION; RATS; RECOMBINANT FUSION PROTEINS; RNA, ANTISENSE; TRANSFECTION; TRANSGENES;

EID: 1942504296     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2004.tb03204.x     Document Type: Review

References (40)

1. Cancer Statistics in Japan, FFCR, 2003.
2. Haller DG. Future directions in the treatment of pancreatic cancer. Semin Oncol 2002; 29: 31-9.
3. Ryan DP, Willett CG. Management of locally advanced adenocarcinoma of the pancreas. Hematol Oncol Clin North Am 2002; 16: 95-103.
4. Kaufman HL, DiVito J, Horig H. Immunotherapy for pancreatic cancer: current concepts. Hematol Oncol Clin North Am 2002; 16: 159-97.
5. Ghadirian P, Lynch HT, Krewski D. Epidemiology of pancreatic cancer: an overview. Cancer Detect Prev 2003; 27: 87-93.
6. Isaksson B, Jonsson F, Pedersen NL, Larsson J, Feychting M, Permert J. Lifestyle factors and pancreatic cancer risk: a cohort study from the Swedish twin registry. Int J Cancer 2002; 98: 480-2.
7. Michaud DS. The epidemiology of pancreatic, gallbladder, and other biliary tract cancers. Gastrointest Endosc, 2002; 56: S195-200.
8. Sakorafas GH, Tsiotou AG, Tsiotos GG. Molecular biology of pancreatic cancer; oncogenes, tumor suppressor genes, growth factors, and their receptors from a clinical perspective. Cancer Treat Rev 2000; 26: 29-52.
9. Motojima K, Urano T, Nagata Y, Shiku H, Tsunoda T, Kanematsu T. Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumor stage in human pancreatic carcinoma. Am J Gastroenterol 1991; 86: 1784-8.
10. DiGiuseppe JA, Hruban RH, Offerhaus GJ, Clement MJ, van den Berg FM, Cameron JL, van Mansfeld AD. Detection of K-ras mutations in mucinous pancreatic duct hyperplasia from a patient with a family history of pancreatic carcinoma. Am J Pathol 1994; 144: 889-95.
11. Cerny WL, Mangold KA, Scarpelli DG. K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster. Cancer Res 1992; 52: 4507-13.
12. Yanagisawa A, Ohtake K, Ohashi K, Hori M, Kitagawa T, Sugano H, Kato Y. Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation. Cancer Res 1993; 53: 953-6.
13. Aoki K, Yoshida T, Sugimura T, Terada M. Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 1995; 55: 3810-6.
14. Aoki K, Yoshida T, Matsumoto N, Ide H, Sugimura T, Terada M. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation. Mol Carcinog 1997; 20: 251-5.
15. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991; 108: 193-9.
16. Ohnami S, Aoki K, Suzuki K, Ohnami S, Hatanaka K, Yoshida K, Sasaki H, Yoshida T. Expression profiles of pancreatic cancer cell lines infected with antisense K-ras expressing adenoviral vector. Biochem Biophys Res Commun 2003; 309: 798-803.
17. Nakano M, Aoki K, Matsumoto N, Ohnami S, Terada M, Hibi T, Yoshida T. Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K-ras RNA. Mol Ther 2001; 3: 491-9.
18. Weinstein IB. Addiction to oncogenes-the Achilles heal of cancer. Science 2002; 297: 63-4.
19. Villalonga P, Lopez-Alcala C, Bosch M, Chiloeches A, Rocamora N, Gil J, Marai R, Marshall CJ, Bachs O, Agell N. Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling. Mol Cell Biol 2001; 21: 7345-54.
20. Ohnami S, Matsumoto N, Nakano M, Aoki K, Nagasaki K, Sugimura T, Terada M, Yoshida T. Identification of genes showing differential expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumor-genicity. Cancer Res 1999; 59: 5565-71.
21. Behr JP, Demeneix B, Loeffler JP, Perez-Mutul J. Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA. Proc Natl Acad Sci USA 1989; 86: 6982-6.
22. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP. A versatile vector for gene and oligonucletide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995; 92: 7297-301.
23. Aoki K, Furuhata S, Hatanaka K, Maeda M, Remy JS, Behr J-P, Terada M, Yoshida T. Polyethylenimine-mediated gene transfer into pancreatic cancer dissemination in the murine peritoneal cavity. Gene Ther 2001; 8: 508-14.
24. Aoki K, Yoshida T, Matsumot N, Ide H, Sugimura T, Terada M. Gene therapy for peritoneal dissemination of pancreatic cancer by liposome-mediated transfer of herpes simplex virus thymidine kinase gene. Hum Gene Ther 1997; 8: 1105-13.
25. Krasnykh V, Douglas JT. Targeted adenoviral vectors I: transductional targeting. In: Curiel DT, Douglas JT, editors. Adenoviral vectors for gene therapy. San Diego: Academic Press; 2002. p. 205-45.
26. Nicklin SA, White SJ, Watkins SJ, Hawkins RE, Baker AH. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation 2000; 102: 231-7.
27. Belousova N, Krendelchtchikova V, Curiel DT, Krasnykh V. Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol 2002; 76: 8621-31.
28. Hatanaka K, Ohnami S, Miura Y, Yoshida K, Aoyagi K, Sasaki H, Asaka M, Terada M, Yoshida T, Aoki K. A simple and efficient method for constructing an adenoviral cDNA expression library. Mol Ther 2003; 8: 158-66.
29. Ozaki K, Yoshida T, Ide H, Saito I, Ikeda Y, Sugimura T, Terada M. Use of von Willebrand factor promoter to transducer suicidal gene to human endothelial cells, HuVEC. Hum Gene Ther 1996; 7: 1483-90
30. Furuhata S, Ide H, Miura Y, Yoshida T, Aoki K. Development of a prostate-specific promoter for gene therapy against androgen-independent prostate cancer. Mol Ther 2003; 3: 366-74.
31. Hogan WJ, Storb R. Therapeutic applications of non-myeloablative hematopoietic stem cell transplantation in malignant disease. Immunol Res 2003; 28: 1-11.
32. Chawla-Sarkar M, Lindner DJ, Liu Y-F, Williams BR, Sen GC, Silverman RH, Borden EC. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003; 8: 237-49.
33. Pfeffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, Burdens R, Walter MR, Nagabhushan TL, Trotta PP, Pestka S. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998; 58: 2489-99.
34. Gutterman JU. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci USA 1994; 91: 1198-205.
35. Matsubara N, Fuchimoto S, Orita K. Antiproliferative effects of natural human tumor necrosis factor-alpha, interferon-alpha, and interferon-gamma on human pancreatic carcinoma cell lines. Int J Pancreatol 1991; 8: 235-43.
36. Watanabe T, Fuchimoto S, Matsubara N, Iwagaki H, Orita K. Anti-proliferative effect on human pancreatic cancer cells of natural human tumour necrosis factor-beta combined with natural human interferon-alpha or interferon-gamma. J Int Med Res 1992; 20: 112-20.
37. Suzuki K, Aoki K, Ohnami S, Yoshida K, Kazui T, Kato N, Inoue K, Kohara M, Yoshida T. Adenovirus-mediated gene transfer of interferon α improves dimethynitrosamine-induced liver cirrhosis in rat model. Gene Ther 2003; 10: 765-73.
38. http://www.nih.gov/news/panelrep.html
39. http://www.fda.gov/fdac/features/2000/500_gene.html
40. Marshall E. Gene therapy, a suspect in leukemia-like disease. Science 2002; 298: 34-5.